Genomics and Molecular Resources Core

基因组学和分子资源核心

• 批准号: 10007633
• 负责人: Pui-Yan KWOK
• 金额: $ 11.86万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-21 至 2021-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10007633
• 关键词: Address; Adult; Age; Autoantigens; Autoimmune Process; Bioinformatics; Biological Assay; CRISPR/Cas technology; California; Childhood; Clinical; Clinical Data; Collaborations; Collection; Consultations; Data; Data Analyses; Database and Analysis Portal; Disease; Ensure; Epigenetic Process; Faculty; Flow Cytometry; Future; Generations; Genomics; Goals; Growth; Immune; Immunologics; Immunology; Immunophenotyping; Individual; Infrastructure; International; Laboratories; Laboratory Personnel; Laboratory Research; Leadership; Lymphocyte; Management Information Systems; Mass Spectrum Analysis; Medicine; Molecular; Monitor; Mutation; Patients; Phenotype; Play; Pluripotent Stem Cells; Process; Production; Proteomics; Quality Control; Research; Research Infrastructure; Research Personnel; Resources; Rheumatism; Rheumatology; Role; Sampling; San Francisco; Secure; Services; Signal Transduction; Software Tools; Specimen; Statistical Data Interpretation; System; Technology; Testing; Training; Universities; Work; base; biobank; clinical phenotype; cytokine; experience; genome editing; genomic tools; human data; human subject; innovation; interest; microbiome analysis; molecular phenotype; new technology; novel; outreach; phenotypic data; precision medicine; ranpirnase; sample collection; service coordination; success; tool

PROJECT SUMMARY/ABSTRACT – Genomics and Molecular Resources Core The overall goal of our Center is to advance precision medicine in the rheumatic diseases. The Genomics and Molecular Resources (GMR) Core will play a critical role in our Center by facilitating access to biospecimens from well-characterized rheumatic disease patients, and providing consultative and coordination services to ensure appropriate use of genomics, proteomics, and other molecular technologies that have the potential to advance precision medicine in rheumatology. The GMR Core will streamline laboratory research infrastructure, including acquisition, processing, storage and management of biospecimens by consolidating existing rheumatology biospecimens at UCSF and establishing a state-of-the-art Laboratory Information Management System (LIMS) that will enable us to expand sample collection and create an accessible biorepository. These activities will occur within the laboratory of Dr. Pui-Yan Kwok, Co-Director of the GMR Core, whose experience as Faculty Director of the UCSF Genomics Core over the past decade makes him highly qualified to direct these activities. Core leadership will also provide consultation related to the appropriate application of genomics and molecular assays (including proteomic and immunologic phenotyping) and will serve as a liaison between investigators and laboratory personnel to ensure that consistently high quality genomic and molecular phenotyping data are obtained. A panel of genomics and molecular phenotyping experts will serve as consultants for P30 investigators and projects, covering a wide range of expertise including genomics, epigenetics, proteomics, immune phenotyping, lymphocyte signaling, microbiome analysis, and production of pluripotent stem cells. The GMR Core will work closely with the Human Subjects and Clinical Phenotyping (HSCP) Core to coordinate selection of the appropriate rheumatic disease patients and clinical data for Center studies, and with the Integrative Bioinformatics (IB) Core to integrate genomic and molecular data with clinical data for statistical analysis. Key strengths of the GMR Core include the substantial existing rheumatic disease biospecimens that will be consolidated and centrally managed using a state-of-the-art LIMS; internationally renowned experts in genomics and molecular phenotyping for rheumatic, autoimmune and other disorders; facilities for generating state-of-the-art genomics and other molecular phenotyping data from human biospecimens; and visibility locally, nationally, and internationally to facilitate outreach activities of the Center to advance precision medicine in rheumatic disease research.

项目摘要/摘要 - 基因组学和分子资源核心 我们中心的总体目标是进步风湿性疾病中的精确药物。基因组学和 分子资源（GMR）核心将通过支持获得生物测量来在我们的中心发挥关键作用 来自特征良好的风湿病患者，并提供协商和协调服务 确保适当使用具有潜力的基因组学，蛋白质组学和其他分子技术 风湿病学的预先精确医学。 GMR核心将简化实验室研究 基础架构，包括通过合并对生物测量的收购，处理，存储和管理 在UCSF的现有风湿病生物测量并建立最先进的实验室信息 管理系统（LIMS）将使我们能够扩展样本收集并创建一个可访问的 生物座席。这些活动将发生在GMR联合主任Pui-Yan Kwok博士的实验室内。 核心，他在过去十年中担任UCSF基因组学核心核心核心的经验使他 高度有资格指导这些活动。核心领导还将提供与 适当应用基因组学和分子测定（包括蛋白质组学和免疫表型） 并将作为调查人员和实验室人员之间的联络 获得质量基因组和分子表型数据。基因组学和分子面板 表型专家将担任P30调查人员和项目的顾问，涵盖广泛的 专业知识包括基因组学，表观遗传学，蛋白质组学，免疫表型，淋巴细胞信号传导， 微生物组分析和多能干细胞的产生。 GMR核心将与 人类受试者和临床表型（HSCP）核心，以协调适当的风湿性选择 疾病患者和中心研究的临床数据，以及综合生物信息学（IB）核心 综合基因组和分子数据与临床数据进行统计分析。 GMR核心的关键优势 包括将巩固并集中的现有风湿性疾病生物测量 使用最先进的LIM进行了管理；国际知名的基因组学专家和分子专家 风湿性，自身免疫性和其他疾病的表型；生成最先进基因组学的设施 以及来自人类生物测量的其他分子表型数据；在本地，全国和 在国际上促进中心的外展活动，以促进风湿病的精确医学 研究。